Join the Oncology Voice Network. Join for Free
Career Satisfaction and Growth: What factors MUST be considered
MSL career satisfaction company culture evaluation aligning core values effective company research MSL roles evolution

Career Satisfaction and Growth: What factors MUST be considered


Share This Article


Summary

In this episode, Tom Caravela is joined by Beth Kupferer to discuss career satisfaction and adaptation in the MSL field. Beth shares insights from her career journey, emphasizing the importance of evaluating leadership, company culture, and aligning with core values. The conversation delves into effective company research and key interview questions. Beth and Tom explore the evolution of MSL roles and team structures post-COVID, highlighting the significance of networking and adapting to KOL preferences. They also discuss the value of live meetings and conferences in the current landscape. The episode concludes with listener appreciation and a request for feedback.

My guest today is Beth Kupferer, National Director, Women’s Health at AbbVie, and we discuss the factors most important for career satisfaction and growth

Beth discusses…

👉 What people need to know when determining next steps for their careers
👉 How people should research companies prior to making the decision to join
👉 What people should be looking for in a company
👉 What MSLs can do to help grow their career
👉 How critical it is for company values to align with personal values
👉 Questions to prepare and ask during an interview

Click for Source
MSL career satisfaction, company culture evaluation, aligning core values, effective company research, MSL roles evolution

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN